Isomorphic Labs closed a $2.1 billion Series B round, funding meant to scale its AI drug design engine and expand a pipeline of therapeutic programs. The London-based firm, led by CEO Sir Demis Hassabis, said the round was led by Thrive Capital with participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund.
The money is earmarked for three things: continued development of the company's AI drug design engine, internally named IsoDDE; expansion of its pipeline of therapeutic programs; and hiring across AI, engineering, drug design and clinical roles at its London, Cambridge and Lausanne sites.
Hassabis said the company is now focused on scaling what it has built: "Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease."
That framing matters because Isomorphic Labs has spent years building the underlying models before shipping any product, an unusual position for a startup this well capitalized. Its case for the patience rests on strategic partnerships already in place with Novartis, Eli Lilly and Johnson & Johnson, deals the company points to as validation of its AI-first approach to therapeutic design.
Jaderberg made the more concrete claim, saying internal programs have already hit key milestones and identified viable drug candidates: "Our drug design engine works, and it's giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that was previously out of reach." Neither claim arrived with a public benchmark attached. The company did not disclose which internal programs the milestones refer to, or define what makes a candidate viable.
The investor roster is itself worth reading. Thrive Capital founder Joshua Kushner and GV managing partner Krishna Yeshwant both framed their participation in terms of team quality rather than product traction, language typical of a round priced on potential rather than revenue. Continued backing from Alphabet, and comments from Alphabet and Google president and chief investment officer Ruth Porat, point to how closely Isomorphic Labs remains tied to its parent despite operating as an independent company.
None of the company's own materials disclose a post-money valuation for the round.
What the raise confirms, more than anything, is that AI applied to biology remains one of the few subsectors where funding at this scale keeps landing, even as generative AI investment broadly grows more selective. The company's bet is that architecture advances built for language models translate into molecular design. Whether IsoDDE's internal milestones convert into approved therapies, rather than well-funded research programs, will not be answerable for years.
Leave a Reply